Cecilia Boccalini
YOU?
Author Swipe
View article: Mapping Alzheimer's disease heterogeneity with molecular imaging biomarkers
Mapping Alzheimer's disease heterogeneity with molecular imaging biomarkers Open
Background Alzheimer's disease (AD) is neuropathologically defined by the buildup of misfolded proteins such as extracellular amyloid‐β (Aβ) and intracellular tau neurofibrillary tangles. AD also extends beyond these pathological processes…
View article: Creating a multi‐centre Amyloid PET dataset for DLB patients: Design and Methodology
Creating a multi‐centre Amyloid PET dataset for DLB patients: Design and Methodology Open
Background Dementia with Lewy Bodies (DLB) is often misdiagnosed or conflated with Alzheimer’s Disease (AD) due to overlapping clinical presentations and neuropathological features. The presence of AD‐like features correlates with accelera…
View article: Gene‐expression contributions to specific and shared regional vulnerabilities to amyloid, tau, and neurodegeneration in Alzheimer's disease
Gene‐expression contributions to specific and shared regional vulnerabilities to amyloid, tau, and neurodegeneration in Alzheimer's disease Open
Background Protein deposition and neurodegeneration differently affect the brain spatially and temporally in Alzheimer's disease (AD). Here we used imaging transcriptomics to understand the biological and molecular properties underlying re…
View article: Gene‐expression contributions to specific and shared regional vulnerabilities to amyloid, tau, and neurodegeneration in Alzheimer’s disease
Gene‐expression contributions to specific and shared regional vulnerabilities to amyloid, tau, and neurodegeneration in Alzheimer’s disease Open
Background Protein deposition and neurodegeneration differently affect the brain spatially and temporally in Alzheimer’s disease (AD). Here we used imaging transcriptomics to understand the biological and molecular properties underlying re…
View article: Specific centiloid thresholds to describe the continuum of amyloid and tau deposition
Specific centiloid thresholds to describe the continuum of amyloid and tau deposition Open
Background The Centiloid (CL) scale standardizes amyloid PET imaging for consistent measurements across multicenter studies. However, varying thresholds for amyloid positivity create challenges in identifying individuals at risk for cognit…
View article: Visual Classification of Tau-PET Detects 4 Subtypes With Different Long-Term Outcomes
Visual Classification of Tau-PET Detects 4 Subtypes With Different Long-Term Outcomes Open
Visual classification reliably identified 4 tau patterns that differ in global tau load, clinical features, and long-term outcomes, suggesting its clinical usefulness for the detection of higher-risk AD variants. A clinically implementable…
View article: Is early-phase amyloid PET ready for use as neurodegeneration marker?
Is early-phase amyloid PET ready for use as neurodegeneration marker? Open
Alzheimer's disease is marked by accumulation of amyloid-β (Aβ) and abnormal tau, associated with subsequent neurodegeneration. Validated markers of neurodegeneration include brain glucose metabolism, perfusion and atrophy. Dual-phase amyl…
View article: Validating the Amyloid Cascade Through the Revised Criteria of Alzheimer's Association Workgroup 2024 for Alzheimer Disease
Validating the Amyloid Cascade Through the Revised Criteria of Alzheimer's Association Workgroup 2024 for Alzheimer Disease Open
Only approximately one-third of persons with an AA-2024 diagnosis of AD complied with the predictions of the amyloid cascade hypothesis. These results suggest the heterogeneity in how clinical symptoms and pathology are coupled along the A…
View article: Early-phase 18F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer’s disease: a comparison with 18F-FDG-PET and early-phase amyloid-PET
Early-phase 18F-Flortaucipir tau-PET as a proxy of brain metabolism in Alzheimer’s disease: a comparison with 18F-FDG-PET and early-phase amyloid-PET Open
Purpose As dual-phase amyloid-PET can evaluate amyloid (A) and neurodegeneration (N) with a single tracer injection, dual-phase tau-PET might be able to provide both tau (T) and N. Our study aims to assess the association of early-phase ta…
View article: Visual classification of tau‐PET detects four subtypes with different long‐term outcomes
Visual classification of tau‐PET detects four subtypes with different long‐term outcomes Open
Background Substantial variability in tau accumulation patterns in Alzheimer’s disease (AD) population has now become accepted. Subtype and Stage Inference (SuStaIn) has distinguished four distinct spatiotemporal trajectories of tau pathol…
View article: Visual classification of tau‐PET detects four subtypes with different long‐term outcomes
Visual classification of tau‐PET detects four subtypes with different long‐term outcomes Open
Background Substantial variability in tau accumulation patterns in Alzheimer’s disease (AD) population has now become accepted. Subtype and Stage Inference (SuStaIn) has distinguished four distinct spatiotemporal trajectories of tau pathol…
View article: In Vivo Tau and Neurodegeneration Imaging in a Family With the Presenilin 1 Met146Leu Pathogenic Variant
In Vivo Tau and Neurodegeneration Imaging in a Family With the Presenilin 1 Met146Leu Pathogenic Variant Open
In PSEN1 Met146Leu variant carriers, high cortical tau load, without significant atrophy, was present during early memory deficits. In the asymptomatic phase, all biomarkers were negative. More pronounced tau pathology in female than male …
View article: Tracer-Separator
Tracer-Separator Open
Introduction Multiplexed PET imaging revolutionized clinical decision-making by simultaneously capturing various radiotracer data in a single scan, enhancing diagnostic accuracy and patient comfort. Through a transformer-based deep learnin…
View article: Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline
Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline Open
Increasing evidence shows that neuroinflammation is a possible modulator of tau spread effects on cognitive impairment in Alzheimer's disease. In this context, plasma levels of the glial fibrillary acidic protein (GFAP) have been suggested…
View article: Neuroimaging-guided diagnosis of possible FTLD-FUS pathology: a case report
Neuroimaging-guided diagnosis of possible FTLD-FUS pathology: a case report Open
Background This case report presents a patient with progressive memory loss and choreiform movements. Case presentation Neuropsychological tests indicated multi-domain amnestic mild cognitive impairment (aMCI), and neurological examination…
View article: The diagnostic and prognostic value of <scp>tau‐PET</scp> in amnestic <scp>MCI</scp> with different <scp>FDG‐PET</scp> subtypes
The diagnostic and prognostic value of <span>tau‐PET</span> in amnestic <span>MCI</span> with different <span>FDG‐PET</span> subtypes Open
Objectives Mild cognitive impairment presenting with an amnestic syndrome (aMCI) and amyloid positivity is considered due to AD. Many subjects, however, can show an overall very slow progression relevant for differential diagnosis, prognos…
View article: Heterogeneity and overlap in the continuum of linguistic profile of logopenic and semantic variants of primary progressive aphasia: a Profile Analysis based on Multidimensional Scaling study
Heterogeneity and overlap in the continuum of linguistic profile of logopenic and semantic variants of primary progressive aphasia: a Profile Analysis based on Multidimensional Scaling study Open
Background Primary progressive aphasia (PPA) diagnostic criteria underestimate the complex presentation of semantic (sv) and logopenic (lv) variants, in which symptoms partially overlap, and mixed clinical presentation (mixed-PPA) and hete…
View article: Neuroimaging-guided diagnosis of possible FTLD-FUS pathology: a case report
Neuroimaging-guided diagnosis of possible FTLD-FUS pathology: a case report Open
Background: This case report presents a patient with progressive memory loss and choreiform movements. Case presentation: Neuropsychological tests indicated multi-domain amnestic mild cognitive impairment (aMCI), and neurological examinati…
View article: Distinctive clinical and imaging trajectories in SWEDD and Parkinson’s disease patients
Distinctive clinical and imaging trajectories in SWEDD and Parkinson’s disease patients Open
A proportion of patients clinically diagnosed with Parkinson's disease (PD) can have a 123I-FP-CIT-SPECT scan without evidence of dopaminergic deficit (SWEDD), generating a debate about the underlying biological mechanisms. This study inve…
View article: Evaluation of the association between circulatory markers of neuroinflammation and Alzheimer’s disease pathology
Evaluation of the association between circulatory markers of neuroinflammation and Alzheimer’s disease pathology Open
Background Increasing evidence suggests that neuroinflammation and astrogliosis have a prominent role in the spread of pathology and the development of cognitive impairment in Alzheimer’s disease (AD). Circulating plasma markers of neuroin…
View article: Comparing two picture naming tasks in Primary Progressive Aphasia: insights from behavioural and neural results
Comparing two picture naming tasks in Primary Progressive Aphasia: insights from behavioural and neural results Open
Background Picture naming tests are widely used to evaluate language impairments, especially in Primary Progressive Aphasia (PPA). The available instruments differ for type of stimuli and their psycholinguistic properties, known to affect …
View article: Defining tau pathology and neurodegeneration by dual‐phase <sup>18</sup>F‐Flortaucipir PET as diagnostic and prognostic biomarkers in a memory clinic setting
Defining tau pathology and neurodegeneration by dual‐phase <sup>18</sup>F‐Flortaucipir PET as diagnostic and prognostic biomarkers in a memory clinic setting Open
Background 18 F‐Flortaucipir‐PET allows visualization of tau deposits (T) representing a powerful diagnostic and prognostic tool for Alzheimer’s disease (AD). Dual‐phase 18 F‐Flortaucipir‐PET can also evaluate neurodegeneration (N) through…
View article: The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline
The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline Open
INTRODUCTION Tau and neurodegeneration strongly correlate with cognitive impairment, as compared to amyloid. However, their contribution in explaining cognition and predicting cognitive decline in memory clinics remains unclarified. METHOD…
View article: Mapping brain metabolism, connectivity and neurotransmitters topography in early and late onset dementia with Lewy bodies
Mapping brain metabolism, connectivity and neurotransmitters topography in early and late onset dementia with Lewy bodies Open
Background: Early- and late-onset dementia with Lewy bodies (EO-DLB and LO-DLB) are similar in terms of core symptoms. However, LO-DLB presents with more amnestic deficits, while EO-DLB shows a rapid cognitive decline and more severe neuro…